Table 1.
Clinicopathologic Features of Patients
| Characteristic | Autopsy Patients (n=79) |
|---|---|
|
| |
| Age at Diagnosis, years (Mean ± SD) | 62.2±11.4 |
|
| |
| Gender (%) | |
| Male | 44 (56%) |
| Female | 35 (44%) |
|
| |
| Tumor location (%) | |
| Head/Body | 64 (81%) |
| Tail | 14 (18%) |
| NA | 1 (1%) |
|
| |
| Stage at Diagnosis (%) | |
| I/II | 20 (26%) |
| III | 19 (24%) |
| IV | 40 (50%) |
|
| |
| Tumor Differentiationd (%) | |
| Well/Moderate | 27 (34%) |
| Poor | 52 (66%) |
|
| |
| Treatment (%) | |
| Chemoradiation | 32 (41%) |
| Chemotherapy | 34 (43%) |
| None | 13 (16%) |
|
| |
| Median overall survival, months (range) | 10 (0.75 – 58) |
|
| |
| Major Sites Involved by Metastatic Disease at Autopsya (%) | |
| Liver (n=79) | 60 (76%) |
| Lung (n=65)b | 31 (48%) |
| Peritoneum (n=69)c | 41 (59%) |
|
| |
| Number of Sites Involved by Metastatic Disease (%)b,c | |
| 0 | 8 (10%) |
| 1 | 26 (33%) |
| 2 | 29 (37%) |
| ≥3 | 16 (20%) |
|
| |
| Metastatic burden (%) | |
| 0–10 (oligometastatic) | 22 (28%) |
| 11–100 (moderate) | 27 (34%) |
| >100 (widely metastatic) | 29 (37%) |
a
Refers to frequency at each site independently.
b
Data regarding presence of lung metastasis not available for 14 patients.
c
Data regarding presence of peritoneal metastasis not available for 10 patients. na, not available.